Vineet Laboratories Ltd

Appointment of Additional Director

• Appointment of Avula Navaneeswara Reddy as Additional Non-Executive Non-Independent Director.
• Effective date: 14 October 2026; subject to Members' approval at the next general meeting.
• Designation: Non-Executive Non-Independent Director.
• Profile: BA holder; governance experience expected to support board deliberations.
• Not related to any director, KMP, or promoter.
• Not debarred by SEBI or any authority.
• Shareholding: 80 equity shares in the company.

Resignation of Director

• Mr. Vennapusa Premanand Reddy (DIN: 02512956) resigns as Director effective 14 October 2026 due to personal commitments.

Designation Change to Non-Executive Director

• Mr. Vennapusa Premanand Reddy designated as Non-Executive Director effective 14 October 2026.

Relationships between Directors

• No related-party relationships disclosed with other directors.

Vineet Laboratories Ltd - Trading Window closed from 01 October 2026 till 48 hours after the announcement of Standalone Un-Audited Financial results for the Second Quarter and Half year ending on 30th September, 2026

AGM extension approved

• ROC Hyderabad granted two-month extension for Vineet Laboratories' 10th AGM, now due by 30 November 2026.
• Approval letter received on 18 September 2026; ROC order dated 17 September 2026 granted extension.
• Board to fix AGM date, time, venue; notices and annual report to be filed with exchange.

Board approval & audit status

• Audited standalone FY2026 results approved by Board on Aug 25, 2026.
• Note corrected from May 30, 2026.

Audit opinion

• Audit report with unmodified opinion on FY2026 standalone results.

Regulatory disclosure

• Not a Large Corporate per SEBI circular.
• Annexure II includes qualified borrowings disclosure.

Borrowings & capital structure

• Long-term borrowings at year-end: Rs 35.29 Crores.
• Current borrowings at year-end: Rs 3,511.88 Lakhs.
• Equity share capital: Rs 1,920.63 Lakhs.
• Total equity: Rs 4,560.19 Lakhs.

Assets & liquidity

• Total assets: Rs 12,478.34 Lakhs.
• Cash and cash equivalents at year-end: Rs 1,669.52 Lakhs.

FY2026 performance metrics

• Profit before tax: Rs 12,827 Lakhs.
• Depreciation & amortisation: Rs 24,149 Lakhs.
• Finance costs: Rs 488.52 Lakhs.
• Interest income: Rs (1,039) Lakhs.

Board meeting timing

• Board meeting commenced 03:00 PM and concluded 06:30 PM.

Financial highlights

• Board approves audited standalone FY2026 results; audit report unmodified.
• One segment: active pharmaceutical ingredients and intermediates.
• PBT for year ended 31 March 2026: ₹12,827 Lakh.
• PAT for year ended 31 March 2026: ₹111.08 Lakh.
• Total comprehensive income for year: ₹160.40 Lakh.
• EPS (basic and diluted) for the year: ₹1.00.
• Total assets at 31 March 2026: ₹12,478.34 Lakh.
• Total equity at 31 March 2026: ₹4,560.19 Lakh.
• Total liabilities at 31 March 2026: ₹7,918.14 Lakh.
• Auditor NSVR & Associates LLP; unmodified opinion.

Meeting Details

• Date: Tuesday, 25, 2026; time and venue not disclosed.

Key Agenda Items

• Approve Audited Standalone Financial Results for Q4 and FY ended March 31, 2026.

Other Notes

• Trading window closed for insiders until 48 hours after results declaration.

Issue Overview

• Type: Rights Issue; securities: Equity Shares.
• Total issue size and net proceeds disclosed; no undersubscription.
• Board approved revision in deployment plan due to project delays.
• Main objectives: debt repayment, capex for effluent plant, expansion, general corporate purposes.

Utilisation of Proceeds

• Utilisation is as per disclosures; no material deviations observed per MA.
• Delays in objects; deployment revision approved by the Board on 13 Aug 2026.
• Repayment of bank loans: fully utilised.
• Effluent treatment plant: utilised in quarter; some funds remain unutilised.
• Expansion of production facility: partial utilisation; sizeable unutilised balance; revision planned.
• General corporate purposes: utilised in quarter; board-approved allocations.
• Issue expenses: utilised; some proceeds inadvertently used outside objects; reversed August 2026.
• Unutilised proceeds currently parked in monitoring and HDFC/current accounts.

Governance and Compliance

• Approvals status: NA; MA notes no comments on approvals.
• Material events: board-approved revision; delays due to project scope finalisation.
• Board resolution approved deployment revision on August 13, 2026.
• Unutilised funds held in monitoring/account balances.

General Corporate Purpose (GCP)

• GCP: Not applicable; no separate GCP utilisation reported.